A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

NCT02873962 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Peritoneal Cancer
Ovarian Cancer
Fallopian Tube Cancer

Interventions

DRUG: Bevacizumab
DRUG: Nivolumab
DRUG: Rucaparib

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]